Cargando…
Mitochondrial metabolic study guided by proteomics analysis in hepatocellular carcinoma cells surviving long-term incubation with the highest dose of sorafenib
Sorafenib is the standard first-line systemic therapy for hepatocellular carcinoma (HCC). However, the low objective response rates in clinical studies suggest the existence of certain HCC cells that are inherently insensitive to sorafenib. To understand the molecular basis of insensitivity of HCC c...
Autores principales: | Bai, Jing, Liu, Ziqi, Liu, Jiang, Zhang, Saihang, Tian, Yuan, Zhang, Yueshan, Ren, Leiming, Kong, Dezhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949094/ https://www.ncbi.nlm.nih.gov/pubmed/31881007 http://dx.doi.org/10.18632/aging.102582 |
Ejemplares similares
-
Pharmacokinetically guided dosing of oral sorafenib in pediatric hepatocellular carcinoma: A simulation study
por: Panetta, John C., et al.
Publicado: (2021) -
SREBF2–STARD4 axis confers sorafenib resistance in hepatocellular carcinoma by regulating mitochondrial cholesterol homeostasis
por: Yue, Xuetian, et al.
Publicado: (2022) -
Strategies to improve sorafenib efficacy during image-guided treatment of hepatocellular carcinoma
por: Eresen, Aydin, et al.
Publicado: (2021) -
miR-222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma
por: Liu, Kai, et al.
Publicado: (2021) -
Clinical Impact of Vitamin K Dosing on Sorafenib Treatment for Hepatocellular Carcinoma
por: Haruna, Yoshimichi, et al.
Publicado: (2017)